Dr. GPCR announces a strategic partnership with Eurofins Discovery, expanding the community's access to comprehensive, end-to-end GPCR drug discovery services.

Discovery on Target returns to Boston September 28 to October 1, 2026, with GPCR science woven through the Lead Generation Strategies program. Ahead of the meeting, we spoke with four scientists presenting and teaching this year, from partial agonism to obesity targets to fragment screening against orphan receptors.

We tend to call a GPCR antibody “validated,” as if the question were settled. The GeneTex team makes the case for a humbler word, characterized, and for handing the hardest reagents in receptor biology back to the researchers who use them.

On April 29, GPCR scientists filled Pressed Cafe in Boston for the first Dr. GPCR Happy Hour of 2026. No slides, no panels, just the conversations that usually happen in hallways or never at all. Here is what the night looked like, and why it is exactly why this community exists.

Calcium mobilization is one of the fastest and most sensitive ways to measure GPCR activation, but no single readout fits every question. This article walks through how calcium assays work, compares dye-based, aequorin, and genetically encoded detection approaches, and shows how to match the right cell model and assay format to your drug discovery goals.

An amylin receptor is a calcitonin receptor paired with a RAMP, and in a standard cell line the calcitonin side dominates, so the pharmacology reads as calcitonin, not amylin. Here is why that happens, how a low-expression approach fixes it, and what clean cAMP and β-arrestin readouts across AMY1, AMY2, and AMY3 open up for obesity and diabetes drug discovery.

Signaling bias is critical for drug discovery as it forms a selection criterion for agonism. Measuring and quantifying signaling bias reveals which candidates emphasize therapeutically beneficial pathways, and which may be falsely characterized as equivalent by single-pathway assays. Drug discovery programs that do not consider investigating for signaling bias often fail to fully understand the distinction and risk candidate molecules from advancing along the pipeline.

Drug discovery is built on a seductive simplification: identify the malfunctioning receptor, design a compound that engages it, and restore function. But many diseases don't cooperate with that assumption. Alzheimer's, metabolic disease, psychiatric pharmacology — each carries evidence of multi-receptor architecture. Multi-target GPCR pharmacology is not a workaround. In certain disease architectures, it is the pharmacologically correct approach.

GPCR biologic drugs stabilize receptor active states through distributed contact networks small molecules have trouble reproducing. The affinity-trap account, treated as a model rather than a verdict, explains a recurring difficulty at family B GPCR programs.

Spring break at Dr. GPCR — five live Masterclasses scheduled before summer break, examining GPCR science past the equilibrium snapshot. From signaling kinetics to program building, plus two recordings moving into the on-demand library and the community gathering in Boston next week.

The Dr. GPCR community is gathering in Boston on April 29th for an informal evening of real conversation — no presentations, no agenda, just GPCR scientists in one room. Co-hosted with NIS, EuroscreenFast, and Montana Molecular. Space is limited to 50 scientists.

The gap between pharmacological screening and clinical translation has a structural explanation. Generic cell systems (usually) generate clean data — but they don't reflect the tissue environment, disease context, or signaling complexity that determines whether a compound actually works. This week's session examines what changes when you close that gap. Terry Hébert joins the Dr. GPCR community live on April 16 — one of 12+ Masterclasses planned for 2026, all included in Prem

Bryan Roth joins the Dr. GPCR community live this week to examine what standard models don't account for — what happens when GPCR selectivity is encoded at the receptor–transducer interface rather than the receptor alone. This is one of 12+ live Masterclasses planned for 2026, all included in Premium. Also this week: Terry Hébert previews his April 16 session on iPSC-derived models, and a new podcast episode with Joseph Kim on GPCR structural biology and drug discovery.

GPCR internalization does not end signaling — it redirects it. This article explores the assays, beta-arrestin gating mechanisms, and recycling-versus-degradation frameworks that determine receptor fate inside the cell.

Biased signaling is often interpreted through receptor conformations, yet selectivity can also emerge from the stabilization of receptor–transducer complexes. System-dependent variability adds a further layer: signaling profiles shift when biological context changes. This week’s sessions examine both.

Allosteric binding data interpretation challenges traditional assumptions about displacement, affinity, and receptor behavior. This analysis explores how receptor state redistribution, cooperativity, and system context reshape experimental meaning. The result is a more precise framework for interpreting complex pharmacological data.

Classic models explain biased GPCR signaling through ligands that stabilize distinct receptor conformations and thereby favor selective transducer interactions. This remains a powerful framework, but the examples highlighted this week point to an additional route: intracellular modulators that bind at receptor–transducer interfaces, alongside experimental systems that place GPCR signaling in more physiological cellular contexts.

Boston, MA and Irvine, CA — [March 18, 2026] — Dr. GPCR, a nonprofit organization serving the global G protein-coupled receptor (GPCR) research community through education, curated scientific content, and community engagement, today announced a strategic media partnership with GeneTex, a multinational antibody manufacturer with long-standing expertise in reagent development and validation. Anti-GPCR antibody specificity has been a persistent challenge in the field — one with

GPCRs are no longer simple on/off switches. Discover how biased signaling and functional assays are reshaping GPCR drug discovery.

Modern drug discovery produces thousands of compounds—but only pharmacology turns assay signals into predictions. Explore the drug discovery pharmacology principles guiding receptor signaling, potency interpretation, residence time, and real-world drug behavior.

The A₂A adenosine receptor NanoBRET® competitive binding assay enables real-time quantification of ligand–receptor interactions in living cells. By combining NanoLuc-tagged receptors with fluorescent tracers, this approach allows direct measurement of binding displacement, delivering robust pIC₅₀ and pKᵢ values that align with established pharmacology. In this article, we examine the assay principle, validation strategy, and performance across reference antagonists and agonis

The 5th GPCRs-Targeted Drug Discovery Summit is coming to Boston — and DrGPCR will be there. Here's what's on the agenda, who's presenting, and how to register with an exclusive discount.

Quantifying receptor selectivity requires cancelling cell effects, using full curves, and separating bias from subtype preference. Learn the correct framework.

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. New opportunities appear constantly. That is not a flaw. It is the nature of scientific possibility. 👉 The problem begins when ambition grows faster than structure. What feels like momentum can quietly become dilution. More programs. Broader roadmaps. Increasing complexity. And slowly, strategic focus weakens . This is the hidden cost of ambition in biotech leadership. Not failure. Not poo